Cisplatin, 5-fluorouracil and alpha interferon in non small cell lung carcinoma: a toxicity study

Anticancer Res. 1994 Mar-Apr;14(2B):621-5.

Abstract

Data are presented on the general and hematological toxicity of a cisplatin (DDP), 5-fluorouracil (5-FU) and alpha interferon (IFN-alpha) association in patients with stage III B or IV non small cell lung cancer (NSCLC). Twenty patients received DDP (100 mg/mq i.v., day 1) and 5-FU (750 mg/mq/day i.v. continuous infusion, days 1 to 4). In ten of these patients IFN-alpha (3 MU s.c., three times weekly, days 1 to 21) was added. General and hematological toxicity was of a similar degree in both groups. Recombinant granulocyte colony stimulating factor (G-CSF; 5 micrograms/kg b.w. s.c. days 7 to 18) induced a sharp increase in peripheral blood GM-CFU level in patients receiving DDP and 5-FU but not in DDP, 5-FU, IFN-alpha treated patients. The results appear to indicate that IFN-alpha modulation of a DDP, 5-FU combination induces an acceptable degree of toxicity.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Cisplatin / therapeutic use
  • Cisplatin / toxicity*
  • Colony-Forming Units Assay
  • Female
  • Fluorouracil / therapeutic use
  • Fluorouracil / toxicity*
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Interferon-alpha / therapeutic use
  • Interferon-alpha / toxicity*
  • Leukocyte Count / drug effects
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Recombinant Proteins / therapeutic use

Substances

  • Interferon-alpha
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Cisplatin
  • Fluorouracil